You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

FLUDEOXYGLUCOSE F18 Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Fludeoxyglucose F18 patents expire, and when can generic versions of Fludeoxyglucose F18 launch?

Fludeoxyglucose F18 is a drug marketed by Downstate Clincl, 3d Imaging Drug, Biomedcl Res Fdn, Brigham Womens, Cardinal Health 414, Childrens Hosp Mi, Decatur, Essential Isotopes, Feinstein, Hot Shots Nm Llc, Isologic Innovative, Jubilant Draximage, Kettering Medctr, Kreitchman Pet Ctr, Ma General Hosp, Mcprf, Mem Sloan-kettering, Methodist Hosp Res, Midwest Medcl, Mips Crf, Ncm Usa Bronx Llc, Northland, Nukemed, Petnet, Pharmalogic, Pharmalogic Hldgs, Precision Nuclear, Queen Hamamatsu Pet, Sofie, Trustees Univ Pa, Ucla Biomedical, Ucsf Rodiopharm, Uihc Pet Imaging, Univ Michigan, Univ Southern Ca, Univ Tx Md Anderson, Univ Tx Sw Medctr, Univ Utah Cyclotron, Weill Medcl Coll, Wisconsin, and Wusm Cyclotron. and is included in forty-three NDAs.

The generic ingredient in FLUDEOXYGLUCOSE F18 is fludeoxyglucose f-18. There are eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the fludeoxyglucose f-18 profile page.

US Patents:0
Finished Product Suppliers / Packagers: 27
Raw Ingredient (Bulk) Api Vendors: 19
Clinical Trials: 183
Patent Applications: 733
What excipients (inactive ingredients) are in FLUDEOXYGLUCOSE F18?FLUDEOXYGLUCOSE F18 excipients list
DailyMed Link:FLUDEOXYGLUCOSE F18 at DailyMed
Drug patent expirations by year for FLUDEOXYGLUCOSE F18
Recent Clinical Trials for FLUDEOXYGLUCOSE F18

Identify potential brand extensions & 505(b)(2) entrants

Robert Flavell, MD, PhDPhase 1
Michael TopfPhase 1
Xencor, Inc.Phase 1

See all FLUDEOXYGLUCOSE F18 clinical trials

Pharmacology for FLUDEOXYGLUCOSE F18

US Patents and Regulatory Information for FLUDEOXYGLUCOSE F18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Univ Tx Md Anderson FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 203246-001 Jan 13, 2014 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Queen Hamamatsu Pet FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 203771-001 Aug 31, 2015 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Weill Medcl Coll FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 021768-001 Aug 5, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Petnet FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 079086-001 Feb 25, 2011 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sofie FLUDEOXYGLUCOSE F18 fludeoxyglucose f-18 INJECTABLE;INTRAVENOUS 203591-001 Aug 31, 2015 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.